U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT06920420) titled 'Novel Biomarkers Related Xuebijing Injection Improves Sepsis' on March 24.
Brief Summary: Sepsis is a life-threatening clinical syndrome of organ dysfunction caused by dysregulation of the body's response to infection, and is a common cause of ICU admission for critically ill patients, posing a serious threat to human health. The study demonstrated that hemopexin injection significantly reduced the 28-day all-cause mortality rate of sepsis patients, and this study clarified the specific target and molecular mechanism of hemopexin injection in the treatment of sepsis, which may be of great scientific significance and clinical value ...